Celldex Therapeutics (CLDX) EBITDA (2010 - 2026)

Celldex Therapeutics' EBITDA history runs 17 years deep, the most recent figure standing at -$79.8 million for Q1 2026.

• In Q1 2026, EBITDA fell 49.02% year-over-year to -$79.8 million; the TTM figure through Mar 2026 stood at -$284.7 million (down 60.37% YoY), while the FY2025 annual figure was -$258.4 million, down 63.72% from the prior year.
• EBITDA was -$79.8 million for Q1 2026 at Celldex Therapeutics, up from -$81.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$24.8 million in Q1 2022 to a low of -$81.5 million in Q4 2025.
• Historically, EBITDA has averaged -$44.0 million across 5 years, with a median of -$38.2 million in 2023.
• The sharpest annual moves came in 2022 and 2023: EBITDA tumbled 173.29% in 2022, then rose 16.37% in 2023.
• A 5-year view of EBITDA shows it stood at -$25.1 million in 2022, then tumbled by 67.76% to -$42.1 million in 2023, then retreated by 16.46% to -$49.1 million in 2024, then slumped by 66.01% to -$81.5 million in 2025, then increased by 2.05% to -$79.8 million in 2026.
• The last three EBITDA figures came in at -$79.8 million (Q1 2026), -$81.5 million (Q4 2025), and -$66.6 million (Q3 2025), per Business Quant data.